01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

BAY 1163877: Phase I data

Data from 44 evaluable patients with refractory advanced or metastatic solid tumors with high tumor FGFR mRNA levels in the open-label, international Phase I trial showed that 50-800 mg oral twice-daily BAY 1163877 led to...